Docoh
Loading...

NBIX Neurocrine Biosciences

News

From Benzinga Pro
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Announces $112 Price Target
14 Oct 21
News, Downgrades, Price Target, Analyst Ratings
Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and announces $112 price target.
Neurocrine Biosciences To Present New INGREZZA (valbenazine) And ONGENTYS (opicapone) Data At MDS Virtual Congress 2021
10 Sep 21
News, FDA, Events
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson
Looking into Neurocrine Biosciences's Return on Capital Employed
20 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter.
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Stocks That Hit 52-Week Lows On Wednesday
11 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday morning, 67 companies achieved new lows for the year.
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug 21
Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021
6 Aug 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Canaccord Genuity Downgrades Neurocrine Biosciences to Hold, Lowers Price Target to $108
6 Aug 21
News, Downgrades, Price Target, Analyst Ratings
Canaccord Genuity analyst Sumant Kulkarni downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Buy to Hold and lowers the price target from $122 to $108.
Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $110
4 Aug 21
News, Price Target, Analyst Ratings
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $116 to $110.
Neurocrine Biosciences Q2 EPS $0.63 Beats $0.49 Estimate, Sales $288.90M Beat $274.38M Estimate
3 Aug 21
Earnings, News
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.49 by 28.57 percent. This is a 55.63 percent decrease over earnings of $1.42 per share
Earnings Scheduled For August 3, 2021
3 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

Press releases

From Benzinga Pro
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
16 Oct 21
Press Releases
SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
11 Oct 21
Press Releases
SAN DIEGO, Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021.
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
8 Oct 21
Press Releases
SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best known for his urban large-scale mural
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
10 Sep 21
Press Releases
SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2 Sep 21
Press Releases
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that members of the management team will participate at the following virtual investor conferences:
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
3 Aug 21
Earnings, Press Releases
SAN DIEGO, Aug. 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2021.